Basilea Pharmaceutica (BPMUF) News Today → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free BPMUF Stock Alerts $48.15 0.00 (0.00%) (As of 05/21/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16, 2024 | finance.yahoo.comStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaMay 4, 2024 | seekingalpha.comBPMUF Basilea Pharmaceutica AGMay 3, 2024 | finance.yahoo.comBasilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024April 24, 2024 | finance.yahoo.comBasilea shareholders approve all proposals of the board of directors at the annual general meetingApril 24, 2024 | finance.yahoo.comBasilea Pharmaceutica AG (0QNA.L)April 9, 2024 | finance.yahoo.comBasilea awarded CARB-X grant to develop recently acquired novel class of antibioticsApril 4, 2024 | msn.comUPDATE 2-US FDA approves Basilea Pharmaceutica's antibioticApril 4, 2024 | msn.comEuropean stocks rise ahead of inflation data; Basilea shinesApril 4, 2024 | finance.yahoo.comBasilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicationsApril 3, 2024 | reuters.comUS FDA approves Basilea Pharmaceutica's antibioticMarch 11, 2024 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaFebruary 22, 2024 | marketbeat.comBasilea Pharmaceutica AG Expected to Earn FY2024 Earnings of $1.85 Per Share (OTCMKTS:BPMUF)Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Free Report) - Equities research analysts at Edison Inv. Res dropped their FY2024 earnings per share estimates for Basilea Pharmaceutica in a research report issued on Tuesday, February 20th. Edison Inv. Res analyst S. Romanoff now anticipates that the coFebruary 21, 2024 | investing.comBasilea Pharmaceutica AG (BSLN)February 13, 2024 | finance.yahoo.comBasilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolioJanuary 19, 2024 | finance.yahoo.comCresemba® sales in Latin America trigger first sales milestone payment to BasileaJanuary 15, 2024 | markets.businessinsider.comBasilea To Buy Preclinical Antibiotics Program From SpexisJanuary 15, 2024 | finance.yahoo.comBasilea announces acquisition of preclinical antibiotics program from SpexisJanuary 5, 2024 | finance.yahoo.comBasilea provides portfolio status updateDecember 20, 2023 | markets.businessinsider.comBasilea Pharmaceutica Agrees With Athyrium On Early Repayment Of Senior Secured LoanDecember 20, 2023 | finance.yahoo.comBasilea announces accelerated loan repaymentDecember 11, 2023 | finance.yahoo.comBasilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosisDecember 4, 2023 | finance.yahoo.comBasilea Pharmaceutica AG's (VTX:BSLN) top owners are individual investors with 58% stake, while 39% is held by institutionsNovember 20, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this yearNovember 13, 2023 | msn.comPfizer unit in pact with Swiss biotech Basilea to sell rights to antifungalNovember 13, 2023 | finance.yahoo.comBasilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungalOctober 31, 2023 | finance.yahoo.comBasilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agentOctober 19, 2023 | finance.yahoo.comBasilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infectionsOctober 17, 2023 | finance.yahoo.comBasilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023October 2, 2023 | finance.yahoo.comBasilea announces FDA acceptance of New Drug Application for antibiotic ceftobiproleSeptember 28, 2023 | finance.yahoo.comBasilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremiaAugust 15, 2023 | finance.yahoo.comBasilea reports strong revenue and profit growth in first half-year 2023August 4, 2023 | markets.businessinsider.comBasilea Pharma Submits NDA For Antibiotic CeftobiproleAugust 4, 2023 | finance.yahoo.comBasilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiproleJune 8, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to BasileaApril 18, 2023 | finance.yahoo.comBasilea provides update on New Drug Application to the US Food and Drug Administration for antibiotic ceftobiproleFebruary 14, 2023 | markets.businessinsider.comBasilea Pharmaceutica Posts FY ProfitFebruary 14, 2023 | finance.yahoo.comBasilea reports strong financial results 2022 based on successful implementation of new strategyFebruary 7, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from PfizerJanuary 24, 2023 | markets.businessinsider.comBasilea Pharma Expects Net Profit In FY22January 24, 2023 | finance.yahoo.comBasilea reports preliminary operating profit for 2022, significantly above guidanceJanuary 11, 2023 | finance.yahoo.comBasilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio updateJanuary 9, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 20 million sales milestone payment to BasileaDecember 28, 2022 | finance.yahoo.comBasilea announces repayment of 2022 convertible bondsDecember 23, 2022 | finance.yahoo.comBasilea announces regulatory approval of antifungal Cresemba® (isavuconazole) in JapanDecember 19, 2022 | finance.yahoo.comBasilea announces transition milestone for oncology asset BAL0891, triggering milestone payment of USD 4 million by SillaJenDecember 14, 2022 | finance.yahoo.comHere's Why Momentum in Basilea Pharmaceutica AG (BPMUF) Should Keep goingDecember 9, 2022 | finance.yahoo.comIs Basilea Pharmaceutica (BPMUF) Outperforming Other Medical Stocks This Year?November 28, 2022 | finance.yahoo.comHere's What Could Help Basilea Pharmaceutica AG (BPMUF) Maintain Its Recent Price StrengthNovember 2, 2022 | nasdaq.comBasilea Pharma To Sell Preclinical CLK Kinase Inhibitors To Twentyeight-SevenTherapeuticsNovember 2, 2022 | finance.yahoo.comBasilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics Get Basilea Pharmaceutica News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMUF and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Pioneer Says: “The last crypto bull market has begun.” (Ad)Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble. Click here if you’d like to learn more about these five cryptos… BPMUF Media Mentions By Week BPMUF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BPMUF News Sentiment▼0.960.44▲Average Medical News Sentiment BPMUF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BPMUF Articles This Week▼10▲BPMUF Articles Average Week Get Basilea Pharmaceutica News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMUF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KALV News Today APLT News Today VERV News Today ATXS News Today YMAB News Today AVTE News Today ABUS News Today IGMS News Today TVTX News Today LRMR News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:BPMUF) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersNext President (Not Trump. Not Biden.)The Freeport SocietyThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlaceWrite this ticker symbol down…StocksToTradeFamous trader issues shocking June 12th warningTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Basilea Pharmaceutica AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
